• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于阐明乳腺癌耐药机制并预测联合药物治疗的网络建模方法。

A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer.

作者信息

Gómez Tejeda Zañudo Jorge, Scaltriti Maurizio, Albert Réka

机构信息

1Department of Physics, The Pennsylvania State University, University Park, PA 16802-6300 USA.

2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215 USA.

出版信息

Cancer Converg. 2017;1(1):5. doi: 10.1186/s41236-017-0007-6. Epub 2017 Dec 29.

DOI:10.1186/s41236-017-0007-6
PMID:29623959
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5876695/
Abstract

BACKGROUND

Mechanistic models of within-cell signal transduction networks can explain how these networks integrate internal and external inputs to give rise to the appropriate cellular response. These models can be fruitfully used in cancer cells, whose aberrant decision-making regarding their survival or death, proliferation or quiescence can be connected to errors in the state of nodes or edges of the signal transduction network.

RESULTS

Here we present a comprehensive network, and discrete dynamic model, of signal transduction in ER+ breast cancer based on the literature of ER+, HER2+, and PIK3CA-mutant breast cancers. The network model recapitulates known resistance mechanisms to PI3K inhibitors and suggests other possibilities for resistance. The model also reveals known and novel combinatorial interventions that are more effective than PI3K inhibition alone.

CONCLUSIONS

The use of a logic-based, discrete dynamic model enables the identification of results that are mainly due to the organization of the signaling network, and those that also depend on the kinetics of individual events. Network-based models such as this will play an increasing role in the rational design of high-order therapeutic combinations.

摘要

背景

细胞内信号转导网络的机制模型可以解释这些网络如何整合内部和外部输入以产生适当的细胞反应。这些模型可有效地应用于癌细胞,癌细胞在生存或死亡、增殖或静止方面的异常决策可能与信号转导网络节点或边的状态错误有关。

结果

在此,我们基于ER +、HER2 +和PIK3CA突变型乳腺癌的文献,提出了一个全面的ER +乳腺癌信号转导网络和离散动态模型。该网络模型概括了已知的对PI3K抑制剂的耐药机制,并提出了其他耐药可能性。该模型还揭示了比单独抑制PI3K更有效的已知和新型联合干预措施。

结论

使用基于逻辑的离散动态模型能够识别主要归因于信号网络组织的结果,以及那些也依赖于单个事件动力学的结果。这样的基于网络的模型将在高阶治疗组合的合理设计中发挥越来越重要的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/040e/5876695/5ec93dcd6bf0/41236_2017_7_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/040e/5876695/5ec93dcd6bf0/41236_2017_7_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/040e/5876695/5ec93dcd6bf0/41236_2017_7_Fig2_HTML.jpg

相似文献

1
A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer.一种用于阐明乳腺癌耐药机制并预测联合药物治疗的网络建模方法。
Cancer Converg. 2017;1(1):5. doi: 10.1186/s41236-017-0007-6. Epub 2017 Dec 29.
2
Discrete dynamic network modeling of oncogenic signaling: Mechanistic insights for personalized treatment of cancer.致癌信号的离散动态网络建模:癌症个性化治疗的机制见解
Curr Opin Syst Biol. 2018 Jun;9:1-10. doi: 10.1016/j.coisb.2018.02.002.
3
Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines.布尔型表皮生长因子受体(ErbB)网络重建与扰动模拟揭示了不同乳腺癌细胞系中的个体药物反应。
BMC Syst Biol. 2014 Jun 25;8:75. doi: 10.1186/1752-0509-8-75.
4
Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.战略性地选择抑制磷脂酰肌醇3激酶的时机以最大化雌激素受体α阳性、PIK3CA突变型乳腺癌的治疗指数
Clin Cancer Res. 2016 May 1;22(9):2250-60. doi: 10.1158/1078-0432.CCR-15-2276. Epub 2016 Jan 5.
5
Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.HER2 抑制后 PI3K/PTEN/AKT 信号网络中可逆的敏感性-抗性转换的特征。
Cell Signal. 2012 Feb;24(2):493-504. doi: 10.1016/j.cellsig.2011.09.030. Epub 2011 Oct 4.
6
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.针对激活的 PI3K/mTOR 信号通路克服了激素受体阳性乳腺癌临床前模型中 CDK4/6 为基础的治疗的获得性耐药。
Breast Cancer Res. 2020 Aug 14;22(1):89. doi: 10.1186/s13058-020-01320-8.
7
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.雌激素受体阳性乳腺癌中联合磷脂酰肌醇-3-激酶抑制与内分泌治疗的临床前模型研究。
Breast Cancer Res. 2011 Mar 1;13(2):R21. doi: 10.1186/bcr2833.
8
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.在HER2阳性乳腺癌细胞中,为实现最佳抗肿瘤活性,需要将PI3K的直接抑制与双重HER2抑制剂联合使用。
Breast Cancer Res. 2014 Jan 23;16(1):R9. doi: 10.1186/bcr3601.
9
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer.α特异性PI3K抑制剂阿培利司联合抗HER2治疗对HER2阳性/PIK3CA突变乳腺癌的疗效。
Front Oncol. 2023 Jul 4;13:1108242. doi: 10.3389/fonc.2023.1108242. eCollection 2023.
10
Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA in HER2/ER-positive breast cancer.基于转录组和蛋白质组学对PIK3CA改变的HER2/ER阳性乳腺癌中失调的真核起始因子4G、信号转导和转录激活因子3以及Hippo信号通路的鉴定
Breast Cancer Res Treat. 2016 Dec;160(3):457-474. doi: 10.1007/s10549-016-4011-9. Epub 2016 Oct 22.

引用本文的文献

1
Interpretable prediction of drug synergy for breast cancer by random forest with features from Boolean modeling of signaling pathways.利用来自信号通路布尔建模的特征,通过随机森林对乳腺癌药物协同作用进行可解释预测。
Sci Rep. 2025 May 22;15(1):17735. doi: 10.1038/s41598-025-02444-7.
2
CanSeer: a translational methodology for developing personalized cancer models and therapeutics.CanSeer:一种用于开发个性化癌症模型和疗法的转化方法。
Sci Rep. 2025 Apr 29;15(1):15080. doi: 10.1038/s41598-025-99219-x.
3
Improving neuroendocrine tumor treatments with mathematical modeling: lessons from other endocrine cancers.

本文引用的文献

1
A REDUCTION METHOD FOR BOOLEAN NETWORK MODELS PROVEN TO CONSERVE ATTRACTORS.一种经证明可保留吸引子的布尔网络模型约简方法。
SIAM J Appl Dyn Syst. 2013;12(4):1997-2011. doi: 10.1137/13090537X. Epub 2013 Nov 21.
2
Logical modeling of lymphoid and myeloid cell specification and transdifferentiation.淋巴样和髓样细胞的特化和转分化的逻辑建模。
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):5792-5799. doi: 10.1073/pnas.1610622114.
3
Synergistic interactions with PI3K inhibition that induce apoptosis.与 PI3K 抑制协同作用诱导细胞凋亡。
用数学建模改善神经内分泌肿瘤治疗:来自其他内分泌癌的经验教训。
Endocr Oncol. 2025 Feb 5;5(1):e240025. doi: 10.1530/EO-24-0025. eCollection 2025 Jan.
4
scBoolSeq: Linking scRNA-seq statistics and Boolean dynamics.scBoolSeq:将 scRNA-seq 统计与布尔动力学联系起来。
PLoS Comput Biol. 2024 Jul 8;20(7):e1011620. doi: 10.1371/journal.pcbi.1011620. eCollection 2024 Jul.
5
Boolean modeling of breast cancer signaling pathways uncovers mechanisms of drug synergy.布尔模型在乳腺癌信号通路中的应用揭示了药物协同作用的机制。
PLoS One. 2024 Feb 23;19(2):e0298788. doi: 10.1371/journal.pone.0298788. eCollection 2024.
6
Emergent dynamics of underlying regulatory network links EMT and androgen receptor-dependent resistance in prostate cancer.潜在调控网络的紧急动力学将前列腺癌中的上皮-间质转化与雄激素受体依赖性耐药联系起来。
Comput Struct Biotechnol J. 2023 Feb 8;21:1498-1509. doi: 10.1016/j.csbj.2023.01.031. eCollection 2023.
7
NETISCE: a network-based tool for cell fate reprogramming.NETISCE:一种基于网络的细胞命运重编程工具。
NPJ Syst Biol Appl. 2022 Jun 20;8(1):21. doi: 10.1038/s41540-022-00231-y.
8
Influence maximization in Boolean networks.布尔网络中的影响最大化。
Nat Commun. 2022 Jun 16;13(1):3457. doi: 10.1038/s41467-022-31066-0.
9
Patient-specific Boolean models of signalling networks guide personalised treatments.基于信号网络的个体化布尔模型指导个体化治疗。
Elife. 2022 Feb 15;11:e72626. doi: 10.7554/eLife.72626.
10
A multiscale cell-based model of tumor growth for chemotherapy assessment and tumor-targeted therapy through a 3D computational approach.一种基于多尺度细胞的肿瘤生长模型,通过 3D 计算方法进行化疗评估和肿瘤靶向治疗。
Cell Prolif. 2022 Mar;55(3):e13187. doi: 10.1111/cpr.13187. Epub 2022 Feb 7.
Elife. 2017 May 31;6:e24523. doi: 10.7554/eLife.24523.
4
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.脑微环境通过HER3激活介导管腔型乳腺癌对PI3K抑制的抗性。
Sci Transl Med. 2017 May 24;9(391). doi: 10.1126/scitranslmed.aal4682.
5
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.PI3K/AKT/mTOR信号通路改变的泛癌蛋白质基因组图谱
Cancer Cell. 2017 Jun 12;31(6):820-832.e3. doi: 10.1016/j.ccell.2017.04.013. Epub 2017 May 18.
6
Modeling the response of a tumor-suppressive network to mitogenic and oncogenic signals.构建抑瘤网络对有丝分裂原和致癌信号响应的模型。
Proc Natl Acad Sci U S A. 2017 May 23;114(21):5337-5342. doi: 10.1073/pnas.1702412114. Epub 2017 May 8.
7
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.从10000例患者的前瞻性临床测序中揭示的转移性癌症的突变图谱。
Nat Med. 2017 Jun;23(6):703-713. doi: 10.1038/nm.4333. Epub 2017 May 8.
8
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.PI3K信号通路通过表观遗传调节因子KMT2D调控乳腺癌中雌激素受体依赖的转录。
Science. 2017 Mar 24;355(6331):1324-1330. doi: 10.1126/science.aah6893.
9
Gene regulatory network underlying the immortalization of epithelial cells.上皮细胞永生化背后的基因调控网络。
BMC Syst Biol. 2017 Feb 16;11(1):24. doi: 10.1186/s12918-017-0393-5.
10
Molecular chess? Hallmarks of anti-cancer drug resistance.分子棋局?抗癌药物耐药性的特征。
BMC Cancer. 2017 Jan 5;17(1):10. doi: 10.1186/s12885-016-2999-1.